Jack Cuzick1, Ivana Sestak2, John F Forbes3, Mitch Dowsett4, Jill Knox2, Simon Cawthorn5, Christobel Saunders6, Nicola Roche7, Robert E Mansel8, Gunter von Minckwitz9, Bernardo Bonanni10, Tiina Palva11, Anthony Howell12. 1. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. Electronic address: j.cuzick@qmul.ac.uk. 2. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. 3. Australian New Zealand Breast Cancer Trials Group, Calvary Mater Newcastle, University of Newcastle, Waratah, NSW, Australia. 4. Academic Department of Biochemistry, The Royal Marsden NHS Trust, London, UK. 5. Breast Care Centre, Southmead Hospital, Bristol, UK. 6. University of Western Australia, Crawley, WA, Australia. 7. Breast Unit, The Royal Marsden NHS Trust, London, UK. 8. Department of Surgery, University of Wales College of Medicine, Cardiff, UK. 9. German Breast Group, Neu-Isenburg, Germany; University Women's Hospital, Frankfurt, Germany. 10. Division of Chemoprevention and Genetics, European Institute of Oncology, Milan, Italy. 11. Pirkanmaa Cancer Society, Tampere, Finland. 12. Genesis Breast Cancer Prevention Centre, Manchester, UK.
Abstract
BACKGROUND: Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease. METHODS: Between Feb 2, 2003, and Jan 31, 2012, we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer (judged on the basis of specific criteria). Eligible women were randomly assigned (1:1) by central computer allocation to receive 1 mg oral anastrozole or matching placebo every day for 5 years. Randomisation was stratified by country and was done with blocks (size six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation; only the trial statistician was unmasked. The primary endpoint was histologically confirmed breast cancer (invasive cancers or non-invasive ductal carcinoma in situ). Analyses were done by intention to treat. This trial is registered, number ISRCTN31488319. FINDINGS: 1920 women were randomly assigned to receive anastrozole and 1944 to placebo. After a median follow-up of 5·0 years (IQR 3·0-7·1), 40 women in the anastrozole group (2%) and 85 in the placebo group (4%) had developed breast cancer (hazard ratio 0·47, 95% CI 0·32-0·68, p<0·0001). The predicted cumulative incidence of all breast cancers after 7 years was 5·6% in the placebo group and 2·8% in the anastrozole group. 18 deaths were reported in the anastrozole group and 17 in the placebo group, and no specific causes were more common in one group than the other (p=0·836). INTERPRETATION: Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women. This finding, along with the fact that most of the side-effects associated with oestrogen deprivation were not attributable to treatment, provides support for the use of anastrozole in postmenopausal women at high risk of breast cancer. FUNDING: Cancer Research UK, the National Health and Medical Research Council Australia, Sanofi-Aventis, and AstraZeneca.
BACKGROUND: Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease. METHODS: Between Feb 2, 2003, and Jan 31, 2012, we recruited postmenopausal women aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer (judged on the basis of specific criteria). Eligible women were randomly assigned (1:1) by central computer allocation to receive 1 mg oral anastrozole or matching placebo every day for 5 years. Randomisation was stratified by country and was done with blocks (size six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation; only the trial statistician was unmasked. The primary endpoint was histologically confirmed breast cancer (invasive cancers or non-invasive ductal carcinoma in situ). Analyses were done by intention to treat. This trial is registered, number ISRCTN31488319. FINDINGS: 1920 women were randomly assigned to receive anastrozole and 1944 to placebo. After a median follow-up of 5·0 years (IQR 3·0-7·1), 40 women in the anastrozole group (2%) and 85 in the placebo group (4%) had developed breast cancer (hazard ratio 0·47, 95% CI 0·32-0·68, p<0·0001). The predicted cumulative incidence of all breast cancers after 7 years was 5·6% in the placebo group and 2·8% in the anastrozole group. 18 deaths were reported in the anastrozole group and 17 in the placebo group, and no specific causes were more common in one group than the other (p=0·836). INTERPRETATION: Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women. This finding, along with the fact that most of the side-effects associated with oestrogen deprivation were not attributable to treatment, provides support for the use of anastrozole in postmenopausal women at high risk of breast cancer. FUNDING: Cancer Research UK, the National Health and Medical Research Council Australia, Sanofi-Aventis, and AstraZeneca.
Authors: Ogheneruona Apoe; Sin-Ho Jung; Heshan Liu; Drew K Seisler; Jayne Charlamb; Patricia Zekan; Lili X Wang; Gary W Unzeitig; Judy Garber; James Marshall; Marie Wood Journal: Am J Hematol Oncol Date: 2016-07
Authors: Amy C Degnim; William D Dupont; Derek C Radisky; Robert A Vierkant; Ryan D Frank; Marlene H Frost; Stacey J Winham; Melinda E Sanders; Jeffrey R Smith; David L Page; Tanya L Hoskin; Celine M Vachon; Karthik Ghosh; Tina J Hieken; Lori A Denison; Jodi M Carter; Lynn C Hartmann; Daniel W Visscher Journal: Cancer Date: 2016-06-28 Impact factor: 6.860
Authors: Jacek Gronwald; Andre Robidoux; Charmaine Kim-Sing; Nadine Tung; Henry T Lynch; William D Foulkes; Siranoush Manoukian; Peter Ainsworth; Susan L Neuhausen; Rochelle Demsky; Andrea Eisen; Christian F Singer; Howard Saal; Leigha Senter; Charis Eng; Jeffrey Weitzel; Pal Moller; Dawna M Gilchrist; Olufunmilayo Olopade; Ophira Ginsburg; Ping Sun; Tomasz Huzarski; Jan Lubinski; Steven A Narod Journal: Breast Cancer Res Treat Date: 2014-06-21 Impact factor: 4.872
Authors: Richard G Roetzheim; Ji-Hyun Lee; William Fulp; Elizabeth Matos Gomez; Elissa Clayton; Sharon Tollin; Nazanin Khakpour; Christine Laronga; Marie Catherine Lee; John V Kiluk Journal: Breast Date: 2014-12-06 Impact factor: 4.380
Authors: Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk Journal: CA Cancer J Clin Date: 2015-08-18 Impact factor: 508.702